Diverse Nrf2 activators (antroquinonol, osthole, citral, or astaxanthin) were nephroprotective in experimental models of FSGS by reducing ROS production, and increasing HO-1, GPX4, and Nrf2 activity [207,208,209,210]. This evidence concerns the gene HMOX1 and focal segmental glomerulosclerosis.